Table 1 Baseline demographics for clinical evaluation committee community-acquired pneumonia patients
Tifacogin n = 251 | Placebo n = 245 | Selected P value | |
|---|---|---|---|
Age in years, mean ± standard deviation | 60.5 ± 15.8 | 60.2 ± 15.1 | |
Gender, number (percentage) | |||
Female | 91 (36) | 100 (41) | |
Male | 160 (64) | 145 (59) | |
Ethnicity, number (percentage) | |||
Caucasian | 207 (82) | 199 (81) | |
Black | 26 (10) | 20 (8) | |
Hispanic | 9 (4) | 12 (5) | |
Asian | 5 (2) | 7 (3) | |
Other | 4 (2) | 7 (3) | |
Baseline APACHE II score | |||
Mean ± standard deviation | 25.6 ± 7.0 | 25.2 ± 6.7 | |
Baseline interleukin-6 | 434.6 | 478.9 | |
Geometric mean (95% CI) | (329.2, 573.6) | (355.1, 645.9) | |
Baseline procalcitonin | |||
Geometric mean (95% CI) | 8.89 (7.15, 11.05) | 8.09 (6.35, 10.31) | |
<2 ng/mL, number (percentage) | 50 (20) | 60 (25) | |
Shock, number (percentage) | 163 (65) | 176 (72) | 0.10 |
Ventilatory support, number (percentage) | 193 (77) | 200 (82) | 0.19 |
Number of organ dysfunctions, number (percentage) | |||
Two or less | 87 (35) | 72 (29) | 0.21 |
Three or more | 164 (65) | 173 (71) | |
Heparin use, number (percentage) | 172 (69) | 167 (68) | |
Organism identified, number (percentage) | 170 (68) | 154 (63) |